Mydecine announces the use of AI to accelerate identification of drug candidates for psychedelics research.
Health Canada’s New SAP Rules: A Q&A With Numinus’ Payton Nyquvest
On January 4, 2022, amendments to Health Canada's Special Access Program took effect that explicitly include access to psychedelic medicine. We asked Numinus' Payton Nyquvest to connect the dots on the impact of these new rules.
The next big trend in mental health treatments? Psychedelic therapy.
Magic mushrooms for your well-being? If you haven't heard about psychedelics being used as a treatment for mental health disorders, this year may change that.
BREAKING: Canada Opens New Legal Pathways For Access To Psychedelics Treatment With Psilocybin And MDMA
In a groundbreaking decision, the Canadian government is changing the way patients can access psychedelic therapies with restricted drugs, including MDMA and psilocybin.
MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC
MindMed announces successfully completing Phase I for 18-MC, with patients receiving dosages of up tp 325 mg.
The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines
Mindset announces a drug development agreement with Japanese-based Otsuka Pharmaceuticals, including a $5 million strategic investment in Mindset.
Value, Growth and Opportunity: Why Psychedelic Stocks Are Poised To Rebound In 2022
After a tough year for stock performance in 2021, we lay out why the psychedelic drug industry is poised to bounce back strongly in 2022.
Texas Further Embraces Psychedelics with Launch of Center for Psychedelic Research and Therapy
Research will focus on how various psychedelics can be used under proper supervision and guidance to treat severe depression, anxiety and PTSD.
The Military Mental Health Crisis, A National Tragedy: Part III
The Military Mental Health Crisis affects over 1 million veterans and has claimed 115,000+ lives in the past 20 years. Fortunately, there is finally hope.
Ketamine therapy can reduce depression symptoms and suicidal thoughts: review
A systematic review of dozens of research papers has found that ketamine therapy has a quick, short-term effect of reducing depression symptoms and suicidal thoughts, making it a promising mental health treatment alternative.
MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder
MindMed announces that the FDA has placed "clinical hold" on its initial IND submission in preparation for its Phase 2b clinical trial for generalized anxiety disorder (GAD).
Novamind Signs Definitive Agreement to Acquire Arizona-based Clinics
Novamind announces a definitive agreement to acquire Arizona-based Foundations for Change, PLC.
